Came N - Search Results

1

Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.

Harrop S, Nguyen PC, Robinson S, Nguyen T, Tiong IS, Came N, Baldwin K, Nguyen V, Chan KL, Blombery P, Westerman D. Harrop S, et al. Among authors: came n. Br J Haematol. 2024 Mar 28. doi: 10.1111/bjh.19427. Online ahead of print. Br J Haematol. 2024. PMID: 38544472 No abstract available.

2

Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.

Nguyen PC, Nguyen V, Baldwin K, Kankanige Y, Blombery P, Came N, Westerman DA. Nguyen PC, et al. Among authors: came n. Br J Haematol. 2023 Aug;202(4):760-770. doi: 10.1111/bjh.18802. Epub 2023 Apr 13. Br J Haematol. 2023. PMID: 37052611

3

Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.

Nguyen PC, Nguyen T, Wilson C, Tiong IS, Baldwin K, Nguyen V, Came N, Blombery P, Westerman DA. Nguyen PC, et al. Among authors: came n. Br J Haematol. 2024 Mar;204(3):910-920. doi: 10.1111/bjh.19252. Epub 2023 Dec 14. Br J Haematol. 2024. PMID: 38098188

4

Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection.

Came N, Nguyen V, Westerman D, Harrison S. Came N, et al. Br J Haematol. 2016 Jun;173(6):947-9. doi: 10.1111/bjh.13655. Epub 2015 Oct 12. Br J Haematol. 2016. PMID: 26456706 Free article. No abstract available.

5

The denominator variable in the quantitation of MRD in acute myeloid leukemia.

Came N, Westerman D, Juneja S. Came N, et al. Am J Hematol. 2015 Nov;90(11):E213-5. doi: 10.1002/ajh.24142. Epub 2015 Oct 12. Am J Hematol. 2015. PMID: 26251233 Free article. No abstract available.

6

Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.

Bayly E, Nguyen V, Binek A, Piggin A, Baldwin K, Westerman D, Came N. Bayly E, et al. Among authors: came n. Cytometry B Clin Cytom. 2020 Sep;98(5):385-398. doi: 10.1002/cyto.b.21893. Epub 2020 Jun 12. Cytometry B Clin Cytom. 2020. PMID: 32530574 Free article.

7

A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.

Fox LC, Tan M, Brown AL, Arts P, Thompson E, Ryland GL, Lickiss J, Scott HS, Poplawski NK, Phillips K, Came NA, James P, Ting SB, Ritchie DS, Szer J, Hahn CN, Schwarer A, Blombery P. Fox LC, et al. Among authors: came na. Br J Haematol. 2020 Sep;190(5):e297-e301. doi: 10.1111/bjh.16819. Epub 2020 Jun 3. Br J Haematol. 2020. PMID: 32488879 Free article. No abstract available.

8

Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.

Pasricha SR, Juneja SK, Westerman DA, Came NA. Pasricha SR, et al. J Clin Pathol. 2011 Jun;64(6):520-3. doi: 10.1136/jcp.2010.088591. Epub 2011 Apr 6. J Clin Pathol. 2011. PMID: 21471142

9

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.

Lew TE, Anderson MA, Lin VS, Handunnetti SM, Came NA, Blombery P, Westerman DA, Wall M, Tam CS, Roberts AW, Seymour JF. Lew TE, et al. Among authors: came na. Blood Adv. 2020 Jan 14;4(1):165-173. doi: 10.1182/bloodadvances.2019000864. Blood Adv. 2020. PMID: 31935286 Free PMC article.

10

Carney DA, Westerman DA, Tam CS, Milner A, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Ritchie D, Came N, Seymour JF. Carney DA, et al. Among authors: came n. Leukemia. 2010 Dec;24(12):2056-62. doi: 10.1038/leu.2010.218. Epub 2010 Oct 21. Leukemia. 2010. PMID: 20962860

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page